Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...
The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...
In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.
The US Food and Drug Administration has approved a new nasal spray for depression treatment. Known as Spravato and ...
The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...
The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.
Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...
The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first ...
The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...
The U.S. Food and Drug Administration has approved a nasal spray that is known to help treat depression.